Usted buscó: resection (Inglés - Maltés)

microscope modified for fluorescence-guided resection;
mikroskopju modifikat għal risezzjoni ggwidata bil-fluworexxenza;

surgical resection was allowed following chemotherapy, before or after radiotherapy.
it-tneħħija kirurġika tat-tumur kienet permessa wara l-kimoterapija, qabel jew wara r-radjuterapija.

in combination with anaesthesia and tumour resection further side effects may occur:
flimkien mal-anestesija u r-risezzjoni tat-tumur, jistgħu jseħħu aktar effetti sekondarji:

173 patients received standard resection without administration of the medicinal product and subsequent radiotherapy.
173 pazjent irċevew tneħħija standard mingħajr ma ngħataw il-prodott mediċinali u r-radjuterapija sussegwenti.

therefore, resection of fluorescing tissue should be weighed up carefully against the neurological function of fluorescing tissue.
għalhekk, ir-risezzjoni ta’ tessut fluworexxenti għandha tiġi evalwata bir-reqqa kontra l-funzjoni newroloġika tat-tessut fluworexxenti.

the resulting fluorescence was used as an intraoperative marker for malignant glioma tissue with the aim of improving the surgical resection of these tumours.
il-fluworexxenza li rriżultat kienet użata bħala marker waqt l-operazzjoni għal tessut ta’ glijomi malinni bil-għan li tittejjeb ir-risezzjoni kirurġika ta’ dawn it-tumuri.

how to identify fluorescence for resection through using the operating microscope in a hands- on setting in the operating room;
kif għandha tiġi identifikata l-fluworexxenza għar-risezzjoni permezz tal-użu ta’ mikroskopju ta’ tħaddim f’ambjent prattiku fis-sala tal-operazzjonijiet;

no patient developed new lesions, worsening hydrocephalus or increased intracranial pressure, and none required surgical resection or other therapy for sega.
l-ebda pazjent ma żviluppa feriti ġodda, aggravar tal-idroċefalus jew żieda fil-pressjoni intrakranjali, u ħadd ma kellu bżonn ta’ resezzjoni kirurġika jew terapija oħra għal sega.

adverse reactions observed after the use of this medicinal product for fluorescence-guided glioma resection are divided into the following two categories:
ir-reazzjonijiet avversi li kienu osservati wara l-użu ta’ dan il-prodott mediċinali għar-risezzjoni ta’ glijoma ggwidata bil-fluworexxenza huma mqassmin fiż-żewġ kategoriji li ġejjin:

after resection of primary gist, patients were randomised to one of the two arms: glivec at 400 mg/day or matching placebo for one year.
wara t-tneħħija b’operazzjoni ta’ gist primarju, il-pazjenti kienu randomised għal waħda minn żewġ fergħat: glivec f’doża ta’ 400 mg/jum jew plaċebo jaqbel miegħu għal sena.

mepact is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection.
mepact huwa indikat għat-tfal, adoloxxenti u adulti żgħazagħ għat-trattament ta’ osteosarkoma mhux metastatika ta’ grad għoli u risettibbli wara risezzjoni kirurġika li tkun sħiħa u makroskopika.

side effects are divided into the following two categories: immediate side effects after having taken gliolan and before anaesthesia combined side effects of gliolan, anaesthesia, and tumour resection.
effetti sekondarji jinqassmu fiż-żewġ kategoriji li ġejjin: effetti sekondarji immedjati wara li tkun ħadt gliolan u qabel l-anestesija effetti sekondarji kkombinati ta’ gliolan, l-anestesija, u t-tneħħija tat-tmur.

patients were included who had a histological diagnosis of primary gist expressing kit protein by immunochemistry and a tumour size ≥ 3 cm in maximum dimension, with complete gross resection of primary gist within 14-70 days prior to registration.
il-pazjenti li kienu nklużi kellhom dijanjosi istoloġika ta’ gist primarju li kien jesprimi l-proteina kit permezz ta’ immunokimika u d-daqs tat- tumur ≥ 3 ċm fl-akbar kejl, bi tneħħija għalkollox ta’ gist primarju b’operazzjoni fi żmien 14-70 jum qabel ma nkitbu.

in a phase iii trial with 349 patients with suspected malignant glioma amenable to complete resection of contrast-enhancing tumour were randomised to fluorescence-guided resection after administration of 20 mg/kg body weight 5-ala hcl or conventional resection under white light.
fi prova klinika ta’ fażi iii bi 349 pazjent suspettati bi glijoma malinna li toqgħod għal tneħħija kompleta ta’ tumur li jkabbar il-kuntrast, il-pazjenti ntgħażlu b’mod każwali għal tneħħija ggwidata bil-fluworexxenza wara l-għoti ta’ 20 mg/kilogramm ta’ piż tal-ġisem 5-ala hcl jew tneħħija konvenzjonali taħt dawl abjad.